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ABSTRACT
Overexpression of protein tyrosine phosphatase PTP4A oncoproteins is common 
in many human cancers and is associated with poor patient prognosis and survival. 
We observed elevated levels of PTP4A3 phosphatase in 79% of human ovarian 
tumor samples, with significant overexpression in tumor endothelium and pericytes. 
Furthermore, PTP4A phosphatases appear to regulate several key malignant 
processes, such as invasion, migration, and angiogenesis, suggesting a pivotal 
regulatory role in cancer and endothelial signaling pathways. While phosphatases 
are attractive therapeutic targets, they have been poorly investigated because of 
a lack of potent and selective chemical probes. In this study, we disclose that a 
potent, selective, reversible, and noncompetitive PTP4A inhibitor, JMS-053, markedly 
enhanced microvascular barrier function after exposure of endothelial cells to 
vascular endothelial growth factor or lipopolysaccharide. JMS-053 also blocked the 
concomitant increase in RhoA activation and loss of Rac1. In human ovarian cancer 
cells, JMS-053 impeded migration, disrupted spheroid growth, and decreased RhoA 
activity. Importantly, JMS-053 displayed anticancer activity in a murine xenograft 
model of drug resistant human ovarian cancer. These data demonstrate that PTP4A 
phosphatases can be targeted in both endothelial and ovarian cancer cells, and 
confirm that RhoA signaling cascades are regulated by the PTP4A family.
INTRODUCTION
Aberrant intracellular signaling is a recurrent feature 
of human cancers that is often reflected in substantial 
changes in pathways involving protein phosphorylation 
and dephosphorylation. Most protein tyrosine kinases are 
responsive to extracellular signals, but they are frequently 
mutated or dysregulated, promoting uncontrolled 
proliferation and enhanced cell survival. Despite 
substantial advances in the development of kinase-
targeted therapeutics, these agents have thus far had little 
impact on ovarian cancer (OvCa) patient survival, which 
remains stubbornly at ~45% five years after diagnosis. 
OvCa tumors are genetically complex and lack common 
molecular drivers [1]. Since protein tyrosine phosphatases 
(PTPs) appear to have a major role in the malignancy of 
cancer [2], we have initiated a program to develop small 
molecule probes to explore new therapeutic opportunities. 
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Studies with patient-derived tumor samples indicate 
a high level of expression of protein-tyrosine phosphatase 
4A (PTP4A, also known as PRL) family members, and 
particularly PTP4A3 in ovarian cancers [3-6]. Elevated 
PTP4A3 expression has also been correlated with poor 
patient prognosis and metastatic processes in several 
cancer types [6-8]. While definitive endogenous PTP4A 
substrates have yet to be identified, genetic studies clearly 
implicate PTP4A in important cancer-associated signaling 
processes, thereby supporting a pivotal role for this PTP 
family in tumorigenesis [9-13]. Excess PTP4A promotes 
RhoA activation through a non-canonical interaction 
with the Src homology 3 domain of p115 RhoGTPase-
activation protein [9]. PTP4A3 is highly expressed in the 
tumor-associated endothelium [3, 14], which has a central 
role in metastases formation and angiogenesis [12]. The 
altered microenvironment in tumors, including high 
concentrations of the potent vasodilator VEGF, creates 
a dysfunctional endothelium, which loses critical barrier 
properties. VEGF promotes the transcription of PTP4A3 
through Myocyte Enhancer Factor 2C [15], and it has been 
documented that the loss of PTP4A3 attenuates VEGF-
mediated vascular permeability in vivo [13]. The formation 
of OvCa peritoneal ascites is driven by vasodilation 
and loss of vascular membrane integrity, which enables 
tumor cell dissemination [13, 16]. Therefore, PTP4A3 
phosphatase appears to influence the function of both 
tumor and stromal cells.
The interrogation of PTP4A3’s biochemical function 
and ability to serve as a therapeutic target would be 
greatly facilitated by potent and selective small molecule 
inhibitors. Although several candidates have been studied, 
including pentamidine, ginkgetin, sciadopitysin, emodin, 
BR-1, and some cyano-2-ene esters, most are neither 
potent (i.e., IC50>25 µM) nor specific for PTP4A3. Current 
inhibitors are also frequently encumbered by structural 
liabilities, such as redox, metal-chelating, and electrophilic 
properties (reviewed in [17]). A thienopyridone was 
previously found to be a sub-micromolar PTP4A3 inhibitor 
(in vitro IC50~150 nM) with considerable selectivity 
against 11 other phosphatases [18]. This compound 
suppressed anchorage-independent cancer cell growth 
in soft agar [18], but there is no available information 
about its in vivo activity. Our group recently designed and 
synthesized a novel iminothienopyridinedione, JMS-053, 
which proved to be a potent PTP4A3 inhibitor (in vitro 
IC50~20 nM) [19]. Herein, the biochemical properties of 
JMS-053, including the inhibition of OvCa cell migration 
and spheroid growth, and the attenuation of in vivo tumor 
growth, are reported. Moreover, the discovery of a new 
role for PTP4A3 in controlling microvascular endothelial 
barrier function was also identified. Finally, JMS-053 
served as a critical tool compound in identifying RhoA 
functions as a distal signaling convergence point for 
PTP4A activity in both endothelial and tumor cells. 
RESULTS
Ptp4a3 is amplified in serous cystadenocarcinoma 
and highly expressed in OvCa tumors
Ptp4a3 is located in chr8q24, which is one of the 
most commonly amplified chromosomal regions in human 
cancers, including OvCa, suggesting a fundamental role in 
tumor maintenance or dissemination [20]. Previous studies 
of PTP4A3 expression profiles in OvCa used small sample 
sizes. Therefore, the most recent TCGA database from 594 
patients (September 2017) (https://tcga-data. nci.nih.gov/
tcga/) was analyzed, and Ptp4a3 amplification in ~33% 
of the ovarian serous cystadenocarcinomas (Figure 1A) 
and exceptionally high mRNA expression compared to the 
13,860 genes examined in the companion RNASeqV2 data 
from 307 TCGA OvCa patients was confirmed (Figure 
1B, Supplementary Figure 1A). Notably, PTP4A3 was 
rarely deleted or mutated. Because an increase in PTP4A1 
or PTP4A2 mRNA was not observed, we subsequently 
focused primarily on PTP4A3 in OvCa. 
Immunohistochemical analysis of human 
patient tumor samples from the University of Virginia 
Biorepository revealed PTP4A3 protein overexpression 
in 45/57 (79%) primary OvCa tumors (Table 1), as well 
as in the tumor endothelium and pericytes (Figure 1C-
1D). These results provide further support that PTP4A3 
overexpression occurs in human OvCa and add to 
its attractiveness as a candidate for pharmacological 
interrogation in both malignant and stromal populations 
within OvCa tumors.
JMS-053 is a potent, specific, reversible, allosteric 
inhibitor of PTP4A3 phosphatase activity
The recently synthesized small molecule JMS-053 
has an in vitro IC50 against human recombinant PTP4A3 
of 18 nM, and currently is the most potent known inhibitor 
of this enzyme. It is a significant improvement over 
thienopyridone, which has an IC50 of ~150 nM for PTP4A3 
(Figure 2A-2B) [19]. A close structural analog of JMS-
053, JMS-038, was inactive at concentrations as high as 
100 µM, and therefore serves as a useful negative control 
compound (Figure 2A-2B). Furthermore, no structurally 
similar compounds with a 2D Tanimoto score of ≥0.8 were 
found during a search of the PubChem and ChemSpider 
databases, supporting the structural uniqueness of the 
JMS-053 chemotype. JMS-053 is a reversible PTP4A3 
inhibitor, as indicated by dilution studies (Figure 2C). 
Reversible inhibition further distinguishes JMS-053 
from many other PTP inhibitors, which frequently are 
irreversible, either because they form covalent adducts 
or generate species that oxidize the catalytic Cys [17]. 
Similar to thienopyridone, JMS-053 behaved as a 
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noncompetitive inhibitor of the 6,8-difluoro-4-methyl-
umbelliferyl phosphate (DiFMUP) substrate (Figure 2D. 
Supplementary Figure 1B). JMS-053 also had significantly 
improved in silico drug-like properties compared to the 
less active thienopyridone (Supplementary Table 1). 
Profiling JMS-053 against a panel of 25 other phosphatases 
(Figure 3A-3C, Table 2) and 50 kinases (Supplementary 
Table 2) showed that this chemotype was highly specific 
for the PTP4A family despite its rather small mass. The 
PTPs surveyed were broadly representative of the major 
human superfamily members, including three receptor-like 
PTPs, ten cytosolic PTPs, and five closely related dual-
specificity phosphatases. This specificity was irrespective 
of whether one compared the amino acids in the catalytic 
domain (Figure 3A) or the full-length protein (Figure 3B-
3C). JMS-053 also inhibited the two homologous PTP4A 
family members, PTP4A1 and PTP4A2, with IC50 values 
of 50 ± 14 and 53 ± 8 nM, respectively. Because both 
PTP4A1 and PTP4A2 also have oncogenic properties 
and are overexpressed in cancer, a pan-PTP4A family 
inhibition profile may be a valuable attribute for a small 
molecule therapeutic [5, 17]. Comparatively minimal 
inhibition was detected with the other phosphatases or 
kinases using a 1 µM screening concentration, with the 
exception of CDC25B and p38α, which were inhibited 
by ~50%. Overall, JMS-053 showed at least a 20-fold 
selectivity for the PTP4A enzymes. 
Based on kinetics studies, the Ki of JMS-053 for 
PTP4A3 was 18 nM. Initial attempts to co-crystalize 
JMS-053 with PTP4A3, however, have been unsuccessful. 
Figure 1: PTP4A3 expression is elevated in OvCa tumors. Panel A. The Ptp4a3 gene was amplified in 33% of the tumors of 
OvCa patients found in the TCGA Provisional database (594 total patients). Panel B. PTP4A3 mRNA was the most abundant mRNA in 
TCGA OvCa tumors as determined by RNAseq (307 OvCa patients). cBioPortal computes the relative expression of an individual gene in 
the tumor to the gene’s expression distribution in a reference population. The reference population is defined as all samples that are diploid 
for the gene in question or all profiled samples. Panel C. Immunohistochemical staining of OvCa patient tumor tissue showed enhanced 
PTP4A3 protein expression. Panel D. Enhanced PTP4A3 protein expression of PTP4A3 was seen in OvCa vascular endothelial cells and 
pericytes. 
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Figure 2: Structure, inhibitory activity, mechanism of action, and PTP4A binding of JMS-053. Panel A. Chemical structure 
of thienopyridone, JMS-053 and its inactive analog JMS-038. Panel B. PTP4A3 inhibition by JMS-053 using a full-length recombinant 
human PTP4A3 and DiFMUP as the substrate. ■, JMS-053; ▲, JMS-038; ■, thienopyridone. Panel C. Reversible PTP4A3 inhibition by 
JMS-053. Full length PTP4A3 was treated with a concentration of JMS-053 equal to the IC50 or 10-fold higher, namely 18 or 180 nM, 
respectively. Pre-incubated (Pre-I) samples were exposed to a concentration of JMS-053 that was 10-fold higher than the IC50 for 30 min 
and then diluted to 18 nM, (IC50). Enz, enzyme. Panel D. Lineweaver Burk plot indicated noncompetitive inhibition by JMS-053. Panels 
B-D, Bars = SEM, N = 8. Panel E. Thermal shift assay for PTP4A3 protein (Tm = 50.5ºC) showing destabilization by 100 µM JMS-053 
(Tm = 47.5ºC) and by 100 µM thienopyridone (Tm = 48.8
oC). JMS-038 (100 µM) produced no significant thermal shift. Panel F. Proposed 
noncompetitive binding mode of JMS-053 (magenta carbons) with PTP4A3. Hydrogen bonds are shown with yellow dashes, and WPD 
loop residues W68PFDD72 are indicated by the red cartoon. For reference, active site residue C104 is shown with cyan carbons.




I II III IV
High Grade Serous 41/52 (79%) 11 11 14 16
Endometrioid 2/2 (100%) 0 1 0 1
Mucinous 1/1 (100%) 0 0 1 0











Therefore, PTP4A3 thermal denaturation profiling was 
conducted using SYPRO orange dye, an environmentally 
sensitive fluorophore that exhibits increased fluorescence 
on binding to hydrophobic protein segments. A Tm of 50.5 
± 0.6ºC (n = 3) was obtained for the apo protein lacking 
the ligand, while adding JMS-053 (100 μM) produced 
a ∆Tm of 3.0ºC or a destabilizing effect against PTP4A3 
indicative of ligand binding [21] (Figure 2E). This ∆Tm 
exceeded the 1.7oC shift seen with a similar concentration 
of the much less potent thienopyridone. The negative 
control JMS-038 (100 μM) showed no effect on PTP4A3 
stability. The recently available X-ray structure of 
PTP4A3 in a complex with CNNM3 (PDB 5TSR) was 
used to identify possible PTP4A3 binding modes for 
JMS-053 [22]. Based on computational docking studies 
with an energy refined structure, a putative binding site 
in the closed conformation was identified. In agreement 
with a noncompetitive mechanism (Figure 2D and 2F), 
the putative allosteric site is removed from the active 
site, and is located in a pocket that is flanked by the α3, 
α4, and α6 helices, and the WPD loop. As the highly 
flexible WPD loop clamps down on the active site, the 
imine moiety of the inhibitor can engage in a hydrogen 
bond with D72. As a result, this acidic residue would 
no longer be available to support enzymatic activity 
through interactions with catalytically important P-loop 
residues C104 and R110 [23]. Moreover, this tight, well 
desolvated inhibitor binding mode is predicted to hold the 
WPD loop in the closed conformation via: 1) hydrogen 
bonds between the compound’s pyridinedione oxygens 
and the side chain amine and hydroxyl groups of residues 
K144 and Y148, respectively, 2) π-stacking between the 
thienopyridinedione and the Y148 side chain aromatic 
ring, and 3) favorable π-π and hydrophobic contacts 
between the inhibitor’s phenyl substituent and the aromatic 
side chains of residues F70 and W84, as well as the alkyl 
side chains of residues P76, V80, V81, L85, L114, and 
L117, respectively. The proposed JMS-053 binding mode 
(Figure 2F) suggests that the thienopyridone structure is 
less active because it cannot engage in a hydrogen bond 
with K144, while JMS-038 is void of activity because it 
lacks the ability to orient in the proposed binding site such 
that a hydrogen bond with D72 is established. Notably, all 
of the proposed JMS-053 amino acids contacts, with the 
exception of V80, are conserved across all three PTP4A 
family members, which is consistent with this compound’s 
inhibitory profile.
Figure 3: PTP dendrograms. Panel A. PTP phylogenetic tree of the 14 amino acids in the active site as described by Almo et al. [49], 
depicting in red the PTPs tested for in vitro inhibition by JMS-053. JMS-053 inhibitory activity was tested on those phosphatases indicated 
in red. The blue branches indicate tyrosine phosphatases and the orange branches are the dual specificity phosphatases. Panel B. The 
phylogenetic tree represents the alignments of the longest isoform of the full length PTP as described by St-Denis et al. [50]. Marked in red 
are the PTPs that were assayed in this project. Panel C. The phylogenetic tree represents the alignments of the longest isoform of the full 
length dual specificity phosphatase with assayed phosphatases indicated in red.
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PTP4A3 inhibition normalizes trans-
endothelial electrical resistance (TEER) after 
vascular endothelial growth factor (VEGF) or 
lipopolysaccharide (LPS) challenge
The vascular endothelium regulates macromolecular 
and cellular trafficking through the vessel walls. 
Enhanced vascular endothelial permeability is associated 
with OvCa pathogenesis and malignant ascites fluid 
formation, a key characteristic of OvCa that is often 
present at diagnosis [24]. Many substances increase trans-
endothelial permeability including growth factors, such 
as VEGF, proinflammatory factors, such as cytokines, 
and exogenous substances like bacterial LPS. The loss of 
endothelial barrier function could be due, at least in part, 
to elevated levels of VEGF in the tumor microenvironment 
[25]. Because a marked in vivo reduction in VEGF-
induced vascular permeability has been observed in 
mice lacking PTP4A3 [13], the impact of JMS-053 on 
the integrity of MVEC barrier function was evaluated. 
Barrier function was measured by differences in trans-
endothelial electrical resistance (TEER), a method that 
has been repeatedly demonstrated to reflect changes in 
macromolecular permeability and allows for continuous, 
quantifiable, real-time monitoring of barrier function [26, 
27]. Exposure of MVECs to VEGF (100 ng/mL) induced 
a profound disruption or “leakiness” of the endothelial 
barrier function that persisted for at least 22 h (Figure 
4A). The precipitous decrease in endothelial barrier 
integrity after VEGF treatment was normalized when 
MVEC were pretreated for 2 h with 5 µM JMS-053 and 
Figure 4: Pharmacological inhibition of PTP4A3 normalizes VEGF- and LPS-induced decreases in transendothelial 
electric resistance (TEER). Panel A. Confluent MVEC cells were treated with VEGF alone (▲), JMS-053 (5 μM) for 2 h before (■) 
or 3 h after VEGF (100 ng/mL) () exposure (indicated by the black arrow). TEER was monitored for 24 h using ECIS. Resistance was 
normalized to time 0. Data are expressed as mean ± SEM, N = 3, *p < 0.05 versus vehicle control.  Panel B. Confluent MVEC cells 
were pretreated with (■) or without (▲) JMS-053 (5 μM) and 24 h later challenged with LPS (0.5 EU/mL) (LPS treatment indicated by 
the black arrow). Vehicle alone treated cells are indicated with the  symbol. TEER was monitored over time using ECIS. Resistance was 
normalized to time 0. Data are expressed as mean ± SEM, N = 3, *p < 0.01 versus control. Panel C. Confluent MVEC were pretreated 
with 5 μM Compound 43 (■) or vehicle control (▲) 2 h before 0.5 EU LPS (LPS treatment indicated by the black arrow) followed by 
continuous exposure to either Compound 43 or vehicle control or they were treated 3 h after LPS with 5 μM Compound 43 (■). Vehicle 
alone treated cells are indicated with the  symbol. TEER was monitored continuously using ECIS. Data are expressed as the mean ± 
SEM, N = 4. *p < 0.01 versus control. Panels D. and E. The effect of JMS-053 on the LPS induced RhoA activation and Rac1 deactivation 
by phosphorylation. Quantification of Western blot analysis of active RhoA, RhoA, active Rac1 and Rac1 in human MVEC pretreated for 
24 h with vehicle (DMSO) or JMS-053 (5 µM) prior to treatment with vehicle or LPS treatment (0.5 EU/mL) for 1 h. Protein levels were 
normalized to total RhoA or Rac1. Signal intensity of active RhoA and Rac1 was quantified by densitometry. *p < 0.05 versus vehicle (two-
way ANOVA). Data plotted as mean ± SEM. N = 3.
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then continuously exposed to the compound (Figure 4A). 
Post-treatment with JMS-053 at 3 h after VEGF exposure 
normalized endothelial barrier function, indicating the lack 
of a requirement for pretreatment (Figure 4A). 
MVEC barrier dysfunction is also caused by LPS 
and is mediated by RhoA activation [28]. The loss of 
MVEC barrier is frequently caused by changes in the 
actin cytoskeleton where cortically distributed actin is re-
arranged to form stress fibers via activation of RhoA and 
a decrease in Rac1. Exposure to JMS-053 24 h prior to 
LPS treatment prevented LPS-induced disruption of the 
endothelial barrier function (Figure 4B). There was no 
observed mitigation of LPS-induced vascular permeability 
with JMS-053 treatment 3 h after LPS exposure. 
Protection and mitigation of VEGF-induced increased 
endothelial permeability was also observed with a recently 
described inhibitor of PTP4A trimerization Compound 43 
[7] (Figure 4C), which is structurally and mechanistically 
quite distinct from JMS-053. This finding provided strong 
orthogonal support for a role of the PTP4A family in the 
regulation of endothelial permeability. JMS-053 treatment 
blocked both the LPS-mediated RhoA activation and the 
LPS-mediated reduction in Rac1 activation (Figure 3D-
3E). Collectively, these data suggest PTP4A phosphatases 
have a regulatory role in endothelial barrier function 
through the RhoA-Rac1 axis.
JMS-053 inhibits OvCa proliferation, spheroid 
viability, and migration
The antiproliferative effects of JMS-053 were 
compared to the nonspecific PTP4A3 inhibitor BR-1 
[29] and thienopyridone [18] using OvCa cells plated as 
a monolayer in cell culture microtiter plates and treated 
with compounds for a total of 48 h. The most sensitive 
cell line was A2780, with an IC50 for JMS-053 of 600 nM 
(Table 3). OvCa cells that are resistant to either cisplatin 
or paclitaxel remained sensitive to JMS-053. Moreover, 
JMS-053 was 30-44 fold more potent than BR-1 in 
inhibiting the growth of some of the OvCa cell lines and 
was on average 8-fold more potent that thienopyridone 
(Table 3). The negative control compound JMS-038 did 
not significantly inhibit the growth of any of the OvCa 
cell lines at concentrations as high as 50 µM. Response 
to JMS-053 was unrelated to the population doubling 
time as illustrated by the faster growing A2780CP20 
Figure 5: Effect of JMS-053 and control compound treatment on OvCa cell line and human normal ovarian epithelial 
cell spheroid growth. Representative IC50 curves for JMS-053 () and control compound ( ) JMS-038, a structurally related inactive 
JMS-053 analog. Panel A. Relationship between PTP4A3 mRNA expression and IC50 values for JMS-053; Panel B. HeyA8; Panel C. 
HeyA8-MDR; Panel D. A2780; Panel E. A2780CP20; Panel F. SKOV3; Panel G., SKOV3IP1; Panel H. SKOV3TRIP2; Panel I. OVCAR4; 
Panel J. COV362: and Panel K. HI0-180 normal ovarian epithelial cells. Independent assays (N = 3) with N = 4 replicates.
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cells, which have a doubling time of 19.3 h and an IC50 
of 1.1 ± 0.7 µM, compared to the parental A2780 cells, 
which had population doubling time of 27.7 h and an IC50 
of 0.6 ± 0.7 µM. JMS-053 did not inhibit the growth of 
IMR90 fibroblasts. We observed a correlation between 
the IC50 values and PTP4A3 expression (Figure 5A) but 
we have been unsuccessful in quantifying endogenous 
PTP4A3 protein levels in these cells. Others [30] have 
demonstrated posttranslational control of PTP4A3 protein. 
Moreover, PTP4A3 phosphatase activity is regulated by 
SRC-mediated phosphorylation on Y53 [31], which adds 
yet another level of complexity to the analysis.
Because OvCa often presents with ascites fluid 
containing cancer cell aggregates, JMS-053 was evaluated 
using relevant OvCa spheroids and a 48 h exposure. 
OvCa cell line spheroids adopted varied morphological 
features (Supplementary Figure 2). HeyA8 spheroids 
were most responsive to JMS-053 with an IC50 value of 
0.8 µM, and the paclitaxel-resistant HeyA8-MDR cells 
retained sensitivity to JMS-053 with an IC50 of 3.5 µM 
(Figure 5B-5C, Figure 6A, Table 3). A2780, A2780CP20, 
SKOV3IP, SKOV3TRIP2, A2780, A2780CP20, COV362 
and OVCAR4 cells had IC50 values between 1.1-5.5 µM 
(Figure 5D-5E, 5G-5J, Table 3, Supplementary Figure 
3). The least responsive was the SKOV3 parental cell 
line with an IC50 value of 10.5 µM (Figure 5F, Table 3). 
JMS-053 did not reduce normal human ovarian HI0-180 
epithelial cells survival at concentrations up to 25 µM, 
suggesting minimal toxicity at least against this non-
tumorigenic cell population (Table 3, Figure 5K). A 48 h 
Figure 6: Genetic and pharmacological inhibition of PTP4A3. Panel A. JMS-053 but not JMS-038 inhibited HeyA8 cell spheroid 
growth. Images were taken of the spheroids 48 h after plating and 24 h after compound addition. Bar = 100 μm. Panel B. Quantification 
of JMS-053 effects on spheroid area. HeyA8 cells were incubated and treated with different concentrations of JMS-053 () or control 
compound JMS-038 ( ). Brightfield spheroid images were captured 48 h after compound exposure and spheroid area was quantified using 
Harmony software. Panel C. Scratch wound assay. JMS-053 inhibited HeyA8 migration after wounding. Images of the cells were taken 
of the vehicle, JMS-053, and JMS-038 treated HeyA8 cell monolayers 0 and 15 h after the longitudinal scratch. Panel D. Suppression of 
PTP4A3 mRNA levels by shRNA. Treatment of HeyA8 cells with scrambled (SCR) or two different PTP4A3-targeted shRNA for 48 h 
decreased PTP4A3 mRNA, as measured by qRT-PCR. Panel E. Quantification of migration inhibition by shRNA. Confluent HeyA8 cells 
expressing shRNA were longitudinally wounded with a pipet tip and cell migration was measured after 14 h by determining the open area 
remaining from the scratch using multiple points of the cell front and ImageJ Fiji software. Panel F. Quantification of inhibition of cell 
migration by JMS-053. Confluent HeyA8 cells were longitudinally wounded with a pipet tip and cell migration was measured 14 h later as 
described above. JMS-053 but not JMS-038 blocked the migration of HeyA8 cells. *p < 0.05, N = 3. 
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exposure to the control compound JMS-038 did not show 
any effects at concentrations up to 50 µM in any cell lines.
PTP4A3 overexpression promotes, and genetic 
deletion reduces, cancer cell migration [10, 13]. 
Consistent with this observation, JMS-053 significantly 
inhibited HeyA8 cell migration in a scratch wound assay 
at concentrations as low as 750 nM (Figure 6B-6C). 
Similarly, shRNA knockdown of PTP4A3 also diminished 
HeyA8 cell migration, supporting the specificity of 
the JMS-053-induced response (Figure 6D-6E). The 
substantial difference in cellular IC50 values versus the in 
vitro PTP4A3 IC50 value could be due to a combination 
of factors, including cell membrane permeability, 
intracellular compartmentalization, protein binding, and 
compound degradation.
JMS-053 suppresses RhoA activation in OvCa 
cells
The phenotypic impact of genetic and pharmacologic 
PTP4A3 inhibition prompted us to investigate what 
changes in cell signaling drive these PTP4A3-dependent 
cellular behaviors. RhoA activation is known to be 
integral to the promotion of growth, migration, and 
dissemination of tumor cells [32], and elevated PTP4A3 
expression levels are reported to alter RhoA activity [10, 
12, 32]. Therefore, the impact of JMS-053 treatment on 
the activation of RhoA in HeyA8 cells was investigated. 
HeyA8 cells were serum-starved overnight and then pre-
treated with JMS-053 (0.1-1 µM) or vehicle for 30 min 
followed by a 30 min exposure to medium supplemented 
with 10% FBS to stimulate RhoA activation in the 
presence of either JMS-053 or vehicle. JMS-053 treatment 
Figure 7: JMS-053 inhibits RhoA activation in HeyA8 cells and has antitumor activity. Panel A. Cells were starved in 
serum-free RPMI 1640 for 24 h, then activation of RhoA was induced by exposure to 10% serum. Cells were pre-treated with indicated 
concentrations of compounds for 30 min prior to serum stimulation and for 30 min while being stimulated with medium containing 10% 
FBS. GTP bound RhoA in equal amounts of total lysate was quantified by a luminescence based G-LISA RhoA Activation assay. Treatment 
with 0.1-1 μM JMS-053. Constitutively active RhoA was used as a positive control for the binding of GTP-RhoA to G-LISA. The data were 
expressed as relative luminescence units (RLU) and were the mean ± SEM (N = 4). Statistical significance was determined by one-way 
ANOVA and Tukey’s multiple comparison test. *p < 0.05, n.s. = not significant. Panel B. Female, athymic nude mice with HeyA8-MDR 
tumors were injected IP with vehicle or JMS-053 (10 mg/kg) daily for 5 days followed by two days without treatment and four additional 
daily treatments (10 mg/kg). Error bars = SEM. *p < 0.05 (Mann-Whitney). Panel C. Body weight monitoring for 12 days indicates that 
JMS-053 treatment did not cause significant weight loss.
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caused a significant inhibition of RhoA activation at all 
concentrations tested with an IC50 of 0.6 µM (Figure 7A). 
Treatment of HeyA8 cells with the control compound 
JMS-038 (1 µM) had no significant effect compared to the 
DMSO vehicle control. Treatment with PTP4A3 targeted 
shRNA reduced RhoA activation and JMS-053 (500 nM) 
caused no further reduction in RhoA activation consistent 
with PTP4A3 target engagement (Supplementary Figure 
4).
JMS-053 treatment inhibits drug-resistant OvCa 
tumor growth in vivo
Drug resistance remains a challenging aspect of 
OvCa treatment. Therefore, in a pilot study, the in vivo 
activity of JMS-053 was examined using a HeyA8-
MDR nude mouse tumor model. Mice readily tolerated 
an IP dose of 10 mg/kg of JMS-053 and, based on an 
independent pharmacokinetic study by SAI Life Sciences, 
the maximum plasma concentration was reached within 
30 min and plasma concentrations of 225 ng/mL (879 nM) 
were present 8 h after the injection. The area under the 
plasma concentration curve (AUC) was 4.425 h*µg/mL, 
which indicates a sustained presence of compound. Female 
nu/nu mice bearing IP HeyA8-MDR tumors were used, 
because the IP implantation site is very representative of 
the human disease [33]. Tumor bearing mice were treated 
with vehicle or 10 mg/kg JMS-053 over a nine-day period. 
IP OvCa tumors were observed in all vehicle treated mice 
and in 7 of 9 JMS-053 treated mice. The tumors from 
the mice treated with JMS-053 for nine days weighed 
on average 45% less than those from the vehicle treated 
group (Figure 7B). There was no significant difference in 
the body weights of the mice in the two treatment groups 
(Figure 7C), thereby indicating that JMS-053 was well 
tolerated at the doses that were administered.
DISCUSSION
Epithelial OvCa is the most lethal gynecological 
cancer and, unfortunately, it is usually diagnosed at 
advanced stages when treatment strategies are limited. 
Despite an initial response to surgical debulking and 
platinum chemotherapy, recurrent or relapsed disease 
is common. Accumulation of ascites fluid enables the 
dissemination of OvCa cells or spheroid aggregates along 
the peritoneal cavity, a characteristic that differentiates 
OvCa from other metastasizing epithelial-derived cancers. 
The enhanced permeability of the tumor vasculature 
allows for the accumulation of proteins, including growth 
factors, cells, and fluid, and provides a rich tumor-
promoting microenvironment. Thus, OvCa represents 
a disease of hyperpermeability, angiogenesis, cellular 
proliferation, and metastasis.
It has been postulated that the PTP4A phosphatases 
have a nodal role in cancer cell growth, survival, 
metabolism, migration, and invasion [17, 18]. In 
endothelial cells, increased PTP4A3 expression has been 
documented to enhance migration, tube formation, and 
angiogenesis [13, 14]. PTP4A phosphatases interact with a 
variety of protein partners, including cell surface receptors, 
intracellular signaling effectors, actin skeleton proteins, 
and ion channels [17]. Despite the relatively low in vitro 
catalytic activity of PTP4A with artificial substrates, the 
catalytic domain is functionally or structurally relevant 
in oncogenesis because phosphatase-deficient mutant 
proteins are unable to form tumors [34]. The generation of 
a PTP4A-targeted pharmacological small molecule tool set 
should help to uncover the mechanism by which PTP4A 
phosphatases alter cancer cell biology.
JMS-053 is a unique, potent, and selective small 
molecule antagonist of PTP4A3 in vitro phosphatase 
activity that suppresses the migration and decreases the 
viability of OvCa cells, and impedes the in vivo growth 
of OvCa (i.e., HeyA8-MDR) xenografts. Our data are 
consistent with JMS-053-mediated inhibition of RhoA, 
a previously described effector in the PTP4A3 signaling 
Table 2: Specificity profiling of JMS-053
Phosphatase % Activity (Mean ± SD)
PTPRC (CD45) 88 ± 3
DUSP22 91 ± 6
PTPN7 (HePTP) 97 ± 3
ACP1 (LMPTP-A) 95 ± 4
LMPTP-B 99 ± 0
DUSP10 (MKP5) 87 ± 0
PTPN4 (PTP-MEG1) 100 ± 1
CDC25B* 52 ± 6
PTPN9 (PTP-MEG2) 88 ± 5
PTPN1 (PTP-1B) 90 ± 5
PTPN22 94 ± 2
PTPRB (PTPβ) 95 ± 5
PTPRM (RPTPμ) 80 ± 1
PTPN6 (SHP-1) 97 ± 11
PTPN11 (SHP-2) 100 ± 9
PTPN2 (TCPTP) 95 ± 3
DUSP13 (TMDP) 95 ± 1
DUSP3 (VHR) 87 ± 11
PTP4A1* 1 ± 0
PTP4A2* 0 ± 0
PTP4A3* 0 ± 0
PP1α 75 ± 0
PP2A* 99 ± 0
PP5 96 ± 2
YopH (Yersinia) 86 ± 4
Lambda PP (Phage) 72 ± 3
JMS-053 (1 µM) was profiled in vitro with 10 µM 
DiFMUP as a substrate against 26 phosphatases. Assays 
performed by a commercial vendor unless marked with 
an asterisk. N=2.
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pathway [10, 12, 35]. Mechanistically, PTP4A1 has also 
been shown to regulate RhoA activation by binding and 
inhibiting the catalytic activity of p115 RhoGAP [9]. The 
binding interaction has been assigned to amino acids 30-
120 of PTP4A1, which is 80% identical in PTP4A3 and 
contains the catalytic site. Moreover, the proposed binding 
sites for JMS-053 overlaps with the p115 RhoGAP binding 
site. 
The pharmacological phenocopying of effects 
observed in PTP4A3 genetic knockdown models by 
JMS-053 fortifies the hypothesis that PTP4A3 is a 
viable molecular target for OvCa treatment [11, 13]. 
JMS-053 exposure also restored compromised barrier 
function after VEGF or LPS challenge in MVECs, and 
inhibited RhoA activation and sustained active Rac1, a 
pharmacodynamic endpoint of undamaged membrane 
permeability. Complementing these results, a structurally 
distinct small molecule inhibitor of PTP4A trimerization 
[7] also restored compromised barrier function.
RhoA GTPase has well defined roles in the 
regulation of cytoskeletal dynamics. These, in turn, 
impact cell cycle progression and proliferation, migration, 
invasion- and metastasis, which are all key aspects of 
cancer initiation and progression (reviewed in [32, 36]). 
Thus, targeting PTP4A3, upstream of RhoA, can have 
multi-faceted anti-tumor and anti-metastatic effects. 
To a large extent, the endothelial barrier integrity is 
regulated by the small GTPases, Rac1, and RhoA [37], 
which cycle between inactive, GDP-, and active, GTP-
bound configurations. This cycle is regulated by GTPase 
activating proteins, which increase the intrinsic rate 
of GTP hydrolysis and guanine nucleotide exchange 
factors, which in turn promote GTPases into the GTP-
bound state [38]. Rac1 and RhoA exert opposing effects 
on endothelial barrier function by inducing different 
patterns of cytoskeletal and cellular contact remodeling 
[39], often leading to either endothelial barrier protection 
(Rac1) or to endothelial barrier dysfunction (RhoA) 
[40]. Activation of RhoA by inflammatory mediators, 
including LPS, activates ROCK1/2, which consequently 
phosphorylates myosin light chain kinase and leads to 
actomyosin contraction, actin stress fiber formation, and 
disruption of endothelial barrier integrity (reviewed in 
[41]). It is notable that RhoA mediates the activation/
phosphorylation of the ezrin/radixin/moesin proteins 
[42]. Ezrin is a putative phospho-substrate of PTP4A3, 
suggesting that PTP4A3 may not directly dephosphorylate 
ezrin; rather it may inhibit ezrin phosphorylation indirectly 
via down-modulation of RhoA-ROCK activity [43]. 
Similarly, inhibition of PTP4A3 may also prevent myosin 
light chain phosphorylation indirectly via RhoA inhibition. 
Moreover, with small G-proteins, including RhoA, the rate 
of nucleotide exchange is regulated by nucleotide-bound 
magnesium, which regulates the biological activity of the 
GTPase [44]. The magnesium-based regulation of RhoA 
is particularly relevant given recent work suggesting that 
PTP4A phosphatases bind the magnesium transporter 
cyclin M/ancient conserved domain protein (CNNM3) 
via the PTP4A phosphatase active site, thereby regulating 
intracellular magnesium transport [45].
In summary, pharmacological tools provide another 
valuable method to dissect the role of domains in enzymes 
and provide an orthogonal approach to genetic methods. 
We believe that our compound, JMS-053, along with 
other small molecules that have recently been described 
[7], will likely be useful in testing the hypothesis that the 
pharmacological inhibition of PTP4A3 can suppress OvCa 
by targeting both the tumor cell directly and endothelial 
cell hyperpermeability, which enables the infiltration of 
cells and soluble proteins into the tumor microenvironment 
Table 3: Effects of JMS-053 on OvCa monolayer proliferation and spheroid viability
Cell line Monolayer (IC50 µM) Spheroid  (IC50 µM)BR-1 Thieno-pyridone JMS-053 JMS-038 Doubling time (h)a JMS-053 JMS-038
SKOV3 48.3 ± 9.1 28.8 ± 2.2 4.3 ± 1.1 >50 43.3 10.5 ± 1.5 >50
SKOV3IP1 35.2 ± 2.3 31.3 ± 8.5 3.7 ± 0.4 >50 27.8 5.2 ± 0.7 >50
SKOV3TRIP2 46.5 ± 0.3 >50 2.9 ± 0.6 >50 35.8 5.5 ± 2.4 >50
A2780* 26.4 ± 1.0 4.5 ± 0.6 0.6 ± 0.2 >50 27.7 1.1 ± 0.5 >50
A2780CP20** 17.3 ± 2 13.1 ± 06 1.1 ± 0.04 >50 19.3 1.6 ± 0.7 >50
HEYA8* >50 47 ± 4.9 25.2 ± 8.5 >50 19.0 0.8 ± 0.3 >50
HEYA8-MDR** >50 >50 19.1 ± 6.0 >50 20.8 3.5 ± 1.4 >50
OVCAR4 48.5 ± 7.9 15.5 ± 2.4 1.5 ± 0.3 >50 39.8 4.4 ± 2.8 >50
COV362 NDb ND ND ND ND 1.6 ± 0.9 >50
IMR90 ND ND >50 >50 <24 hc ND ND
HI0-180 ND ND ND ND ND >25 >25
Monolayer and spheroid cells were treated for 48 h with compounds. * cisplatin resistant; **, paclitaxel resistant. Mean ± 
SD µM. N=3.
a One determination.
b ND = not determined
c From [43]
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and results in an accumulation of ascites fluid. 
MATERIALS AND METHODS
Compounds and reagents
Thienopyridone, Compound 43, JMS-053, and JMS-
038 (Figure 2A) were synthesized as previously described 
[7, 19]. DiFMUP was purchased from ThermoFisher 
Scientific (Waltham, MA). Dimethyl sulfoxide (DMSO) 
was obtained from VWR (Radnor, PA). All other reagents 
were obtained from Sigma-Aldrich unless otherwise 
indicated. 
Ovarian cancer cell lines
HeyA8, HeyA8-MDR, A2870IP2 (referred to as 
A2870 throughout), A2780CP20, COV362, SKOV3, 
SKOV3IP1, SKOV3TRIP2, and HI0-180 cells were 
obtained from Dr. Anil Sood (MD Anderson Cancer 
Center, Houston, TX) and have been described previously 
[46]. COV362 were obtained from Sigma-Aldrich (St. 
Louis, MO). All cell lines were authenticated by short 
tandem repeat DNA profiling prior to experimental 
studies. OVCAR4 cells were obtained from Charles 
River Laboratories (New York, NY). All cells were 
maintained in RPMI (Life Technologies, Grand Island, 
NY) supplemented with 10% fetal bovine serum (FBS), 
with no antibiotics, and were passaged <20 times. 
The Cancer Genome Atlas datamining
The ovarian serous cystadenocarcinoma dataset 
was accessed and mined through the Cancer Genome 
Atlas (TCGA) Research Network (Provisional 2017) 
(http://cancergenome.nih.gov/). Tumor samples with 
corresponding RNAseq (307 patients) and U133 
microarray mRNA data (535 patients) were used for 
subsequent analysis. 
Immunohistochemical staining and scoring of 
patient OvCa tumors
Fifty-seven high-grade serous ovarian cancer 
specimens were obtained after surgical resection and 
prior to radiation or chemotherapy. Formalin-fixed 
paraffin embedded patient samples were tissue sectioned, 
and immunohistochemical stained for PTP4A3 by the 
University of Virginia Biorepository and Tissue Research 
Facility Core following standard procedures. Tissue and 
tumor sections were stained with anti-PTP4A3 (5 µg/
mL, Abcam (ab82568), Cambridge, MA), which was 
previously used with human breast cancer [47], and 
antigen retrieval was by High hP TR Flex solution (Dako) 
at 97oC for 20 min. The immunogen for the PTP4A3 
antibody was the first 100 amino acids of the protein, 
which are not identical to the first 100 amino acids in 
PTP4A1 and PTP4A2. It is assumed that this amino 
acid difference precludes cross reactivity with PTP4A1 
and PTP4A2, but we cannot exclude that possibility. 
Tumor morphological classification was performed 
in accordance with the American Joint Committee on 
Cancer staging system. The study was approved by the 
Institutional Human Subjects Protection Review Board at 
the University of Virginia and carried out in accordance 
with their standards.
In vitro biochemical analysis of JMS-053 and 
thienopyridone
PTP4A3 activity assays were performed in triplicate 
in 384 well Greiner bio-one black microtiter plates as 
previously described [19] with recombinant His6-tagged 
PTP4A3 and substrate DiFMUP (15 µM) incubated at 
25°C for 30 min in 40 mM Tris-HCl (pH 7.0), 75 mM 
NaCl, 2 mM EDTA, and 4 mM DTT buffer. Reversibility 
assays were performed in a 100 μL total volume using the 
same assay conditions. His6-tagged PTP4A3 (1.25 μg) was 
pre-incubated for 30 min with 10X the IC50 of JMS-053 
(180 nM) and then diluted to 1X IC50 (18 nM). Reactions 
were initiated with the addition of 45 µL of substrate for 
a final DiFMUP concentration of 4 μM (Km). Phosphatase 
activity was expressed as a percent maximal activity. 
To determine the competitive nature of the inhibition, 
we used a previously described assay [19] with fixed 
concentrations of the compounds and DiFMUP substrate 
concentrations that were varied from 2.5-25 μM and the 
data were analyzed with GraphPad Prism version 7.00 
(GraphPad Software, La Jolla CA). 
Phosphatase specificity of JMS-053
The inhibition specificity of JMS-053 was 
determined for 26 phosphatases by Eurofins (Dundee, 
Scotland, UK) with their PhosphataseProfilerTM platform 
using 10 µM DiFMUP as a substrate and fluorescent 
intensity at A360EX/A450EM. Inhibitory effects were 
calculated as the mean percent phosphatase activity 
remaining compared with the activity of the vehicle 
control. Kinase profiling of JMS-053 was performed 
by Luceome Biotechnologies (Tucson, AZ) using their 
luciferase-based KinaseSeekerTM platform. JMS-053 
was evaluated at 1 µM in duplicate in both profiling 
platforms. The CDC25B assays were performed with a 
slight modification to our previously described methods 
[48] using recombinant enzyme and the substrate DiFMUP 
at ~3X the Km (150 µM). PTP4A1 and PTP4A2 assays 
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were performed in triplicate in 384 well microtiter plates 
using the same conditions as for PTP4A3 as indicated 
above. PP2A was a gift from Professor David Brautigan 
(University of Virginia) and was assayed with the substrate 
DiFMUP at ~3X KM (150 µM) in 120 mM Tris-HCl (pH 
7.0), 225 mM NaCl, 0.1% BME, and 0.1% BSA buffer. All 
assays were incubated for 30 min at 25oC. Fluorescence 
was measured using a SpectraMax M5 plate reader 
(Molecular Devices, LLC, Sunnyvale, CA) at A358EX/
A455EM. The human active site phosphatase phylogenetic 
tree comprising 14 amino acids (XXXX(His)(Cys)
XX(Gly)XX(Arg)XX, where X is any amino acid) was 
modeled on the published [49] dendrogram supplemented 
with the alignment of other PTPs tested using ClustaW2 
and the full length amino acid sequence trees were 
modeled using the longest isoform [50].
Computational studies
Drug-like properties for the compounds were 
determined with Data Warrior (http://www.openmolecules.
org/datawarrior/). Chemical similarity analyses were 
performed with PubChem (https://pubchem.ncbi.nlm.nih.
gov) and ChemSpider (www.chemspider.com) using a 
2D Tanimoto score of ≥0.8. Modeling software Maestro 
version v11 (Schrödinger, LLC, New York, NY), and 
Insight 2005 and Discovery Studio v16 (both: Dassault 
Systèmes BIOVIA, San Diego, CA), operating on a 
Dell (Round Rock, TX) Precision T7600 with Red Hat 
(Raleigh, NC) Enterprise Linux 6.7, were used for all 
modeling studies. The three-dimensional (3D) coordinates 
of PTP4A3 were extracted from PDB entry 5TSR [22]; 
the 3D coordinates of inhibitor JMS-053 were obtained 
from the Cambridge Crystallographic Data Centre (CCDC 
number 1476250) [19]. The structure of PTP4A3 was 
energy refined in Insight 2005 using a previously reported 
strategy starting with hydrogens only minimization, 
followed by side-chain relaxation, and finally, all atoms 
optimization until the norm of the gradient was <0.001 
kcal/Å [51]. The RMSD of the energy refined structure 
versus the starting X-ray structure was 1.29 Å, which 
was well within crystallographic resolution. Maestro 
and Discovery Studio binding site detectors were used 
to identify a location for JMS-053 binding in a cavity 
(volume ~ 350 Å2) surrounded by helices α3, 4, 6 and 
loop residues 68 - 78. This cavity was chosen for docking 
studies given that its location was removed from the active 
site, yet in contact with the critical WPD loop. Docking of 
the inhibitor in this site was guided by the constant scoring 
of favorable and unfavorable intermolecular, atom-atom 
contacts using the HINT program (implemented in 
Discovery Studio) as described previously [51]. Briefly, 
an systematic optimization of the binding pose applied 
iterative steps and manual adjustments to the inhibitor 
in Cartesian space, as well as to inhibitor bond torsions, 
in conjunction with adjustments to amino acid side 
chain torsions. The Maestro refine loops algorithm was 
applied to loop residues 68 - 78, followed by all atoms 
minimization of the complex using conjugate gradients in 
Insight 2005 until the norm of the gradient was < 0.001 
kcal/Å.
Thermal shift biophysical validation of JMS-053 
binding
PTP4A3 melting curves were obtained at a protein 
concentration of 16 μM (50 mM Tris 150 mM NaCl, 1 
mM DTT pH 7.4) with 20X SYPRO orange (Invitrogen) 
and a ligand concentration of 100 μM. Fluorescence was 
monitored using a QuantStudio 6 Flex real-time PCR 
system (Applied Biosystems). Scans were measured from 
25oC to 65°C at a scanning rate of 1°C/min. The data were 
analyzed using Derivative methods to assess the melting 
temperature (Tm) using Graphpad Prism as previously 
described [52]. 
Real-time quantitative polymerase chain reaction 
(RT-qPCR)
Total RNA was purified from HeyA8 cells using an 
RNAeasy Plus RNA isolation kit per the manufacturer’s 
protocol (Qiagen, Valencia, CA). A total of 500 ng of 
mRNA were converted to cDNA using the RT2 first strand 
synthesis kit (Qiagen). Primers were obtained from Qiagen 
and PTP4A3 amplification was performed at a final primer 
concentration of 400 nM. Real-time monitoring of the 
qPCR reaction was performed on a BioRad CFX Connect 
thermocycler with RT2 SYBR Green ROX Mastermix 
(Qiagen). The program was run at 95°C for 10 min, and 40 
cycles at 95°C for 15 sec and 60°C for one min. PTP4A3 
gene expression was normalized to human GAPDH and 
β-actin. 
Two-dimensional (2D) viability assay
Compounds were tested for their effects on viability 
using OvCa cell lines and a resazurin-based CellTiter 
Blue (Promega, Fitchburg, WI) 2D assay system with 
previously described procedures [53]. All OvCa cell 
lines were cultured in complete growth medium with 
500 cells/22 μL being seeded into each well of a 384 
well black/clear microtiter plate (VWR). Compounds (3 
μL) were added immediately to produce a final DMSO 
concentration of 0.5% matching the vehicle control 
final DMSO concentration. The positive control wells 
had a final concentration of 10% DMSO. The microtiter 
plates were incubated for 44 h (37°C, 5% CO2) at which 
time 5 μL of the resazurin-based CellTiter Blue reagent 
were added. Following an additional 4 h of incubation 
(37°C, 5% CO2), data were captured on a SpectraMax 
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M5 multimode plate reader with an A560EX/A590EM. 
IC50 values were calculated using GraphPad Prism 7.0 
software. 
Spheroid growth and formation assays
 Exponentially growing OvCa cells were harvested 
and seeded (100 cells/22 µL for HeyA8, HeyA8-MDR 
and HI0-180, and 250 cells/22 µL for OVCAR-4, A2780, 
A2780CP20, SKOV3, SKOV3IP1, SKOV3TRIP2, and 
COV362) in each well of a 384 well ultralow attachment 
U-bottom microplate (Corning, Corning, NY). Plates 
were incubated for 24 h (37oC at 5% CO2) to allow 
for spheroid formation. Compounds (3 μL) were then 
added in final DMSO concentrations of 0.5%, as was 
the vehicle control (0.5% DMSO). The positive control 
wells contained 10% DMSO. The microtiter plates were 
incubated for 48 h (37°C, 5% CO2) and 25 μL of the 
CellTiterGlo 3D reagent (Promega, Fitchburg, WI) was 
added. Plates were incubated with shaking for 30 min 
at room temperature. Luminescence data were captured 
on a SpectraMax M5 multimode plate reader. JMS-053 
effects on OvCa spheroid size were determined using a 
PerkinElmer Operetta CLS high content image analysis 
system (PerkinElmer, Waltham, MA). Exponentially 
growing HeyA8 cells were harvested, seeded (100 cells/22 
µL), incubated, and treated with compound as described 
above. Brightfield spheroid images were captured 48 
h after JMS-053 or JMS-038 exposure using a 10X 
objective. Spheroid area was quantified using Harmony 
software (PerkinElmer). Data were analyzed and IC50 
values calculated using GraphPad 7.0. 
Migration assay
OvCa cell migration was quantified using our 
previously described in vitro scratch wound healing assay 
[13]. For compound treatment studies, HeyA8 cells were 
grown to confluent monolayers in 24 well tissue culture 
plates (BD Biosciences, San Jose, CA). Each well (n = 
3 per compound or control treatment) was scratched 
longitudinally with a pipette tip and incubated for 14 or 
15 h to enable gap closure. Images of the cell migration 
front were captured and the migration area was determined 
by measuring the distance between cell fronts at multiple 
points in the images using ImageJ Fiji software and then 
calculating the open area remaining from the scratch. 
For shRNA studies, HeyA8 cells were seeded at 
5 x 105 cells per well of a six well tissue culture dish. 
At 90% confluency, cells were forward transfected 
with 2.5 µg scrambled or PTP4A3-targeted pGFP-C-
shLentiRNA encoding plasmids (Origene Technologies, 
Rockville, MA) complexed with lipofectamine 3000 (1:3) 
(ThermoFisher). After 16 h, culture medium was replaced. 
Cells were harvested by trypsin treatment at 32 h post-
transfection and reseeded in 12 well microtiter plates at 
2 x 105 cells/well and grown to confluency. The scratch 
wound assay was carried out as described above.
Measurement of endothelial barrier function
The barrier function of endothelial cell monolayers 
grown on electrode arrays was estimated by our previously 
described [26, 27] electric cell-substrate impedance 
sensing (ECIS) method using an ECIS model 1600R 
from Applied BioPhysics (Troy, NY). Experiments were 
conducted on cells seeded at a density of 6 x 104 cells/well 
in 8W10E+ arrays that achieved at least 800Ω baseline 
steady-state resistance and capacitance between 22-29 
nanofarads at a frequency of 4000Hz. Each 0.6 mL well 
of the 8 well arrays had 40 small gold film surface active 
electrodes (2 mm2 area) and a large counter electrode. 
A uniform confluent endothelial monolayer reduced the 
amount of current flowing across the gold electrodes to 
the counter electrode, and thus increased the resistance. 
The transendothelial electrical resistance (TEER) 
measured dynamically across the monolayer reflected 
the combined resistance between the ventral surface of 
the cell and the electrode, reflective of focal adhesion, 
as well as the resistance between cells. Intercellular 
gaps increase current flow and reduce resistance. Thus, 
a change in TEER represented a change in cell-cell 
adhesion and/or cell-matrix adhesion. All experiments 
used primary human lung microvascular endothelial cells 
(MVEC) that were harvested, identified, and cultured 
in-house from fresh specimens obtained from patients 
undergoing pneumonectomy or lobectomy, as previously 
described [54] and in accordance with our Institutional 
Review Board criteria. MVEC were exposed to 100 ng/
mL VEGF, 0.5 endotoxin units (EU) LPS, or vehicle 
control. In some studies cells were pre-treated and then 
continuously treated with 5 μM of JMS-053, JMS-038, or 
Compound 43. In other studies, cells were treated 3 h after 
exposure to VEGF or LPS. Experiments were performed 
in quadruplicate and data were expressed as mean values 
± SE. One-way or two-way ANOVA with Bonferroni 
post-hoc test was performed to determine statistically 
significant differences among groups (p < 0.05).
RhoGTPases activity assay
RhoA activation in HeyA8 cells was detected by 
the luminescence formatted RhoA G-LISA Activation 
Assay (Cytoskeleton Inc., Denver, CO), according to 
manufacturer’s instructions. Following a 24 h serum 
starvation in RPMI supplemented with 0.1% fatty-
acid free bovine serum albumin, HeyA8 cells at ~60% 
confluence were pretreated in serum-free medium for 30 
min with compounds in a final DMSO concentration of 
0.5%, as was the vehicle control. HeyA8 cells were then 
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stimulated for 30 min with RPMI containing 10% FBS 
and the compounds in a final DMSO concentration of 
0.5% and harvested on ice. Total protein was determined 
using Precision Red Advanced protein assay reagent 
(Cytoskeleton Inc.). Fifteen µg of cell lysate protein 
per Rho-GTP affinity well were incubated at 4°C for 
30 min on an orbital shaker to facilitate binding. As a 
positive control, 1 ng of purified recombinant RhoA was 
bound to the affinity well. The provided primary and 
secondary antibodies were used at a 1:250 and 1:500 
dilution, respectively. Luminescence data were captured 
on a SpectraMax M5 multimode plate reader set to 50 
ms integration time following 2 min incubation with 
luminescence detection reagent. 
Human MVEC were pretreated with vehicle 
(DMSO) or JMS-053 (5 µM) prior to vehicle or LPS 
treatment (0.5 EU/mL) for 1 or 24 h. MVEC RhoA 
activation was detected using the bead pull-down format 
RhoA Activation Assay Biochem Kit (Cytoskeleton Inc.). 
Cells were lysed in CelLyticM Lysis Reagent and total 
protein in the lysate was determined with a Pierce BCA 
protein assay (ThermoFisher Scientific). Five hundred µg 
of total cell lysate protein were incubated at 4°C with 80 
µg Rhotekin-RBD protein beads for 1 h rotating. After 
precipitation, the complexes were washed four times with 
the wash buffer, eluted in 2X SDS-PAGE sample buffer, 
immunoblotted, and probed with RhoA antibody. GTP-
bound RhoA detection was performed using a monoclonal 
rabbit RhoA antibody (Cell Signaling, no. 2117) [26]. 
Proteins were visualized using a LICOR Odyssey CLx 
imaging system (Lincoln, NE). Aliquots were taken 
from supernatants prior to precipitation and were used to 
quantify total RhoA. Rac1 activity was determined using 
the Rac Activation Assay Biochem Kit (Cytoskeleton Inc., 
BK-035) per the manufacturer’s instructions. Secondary 
mouse and rabbit antibodies were purchased from LICOR. 
ImageJ software was used to perform densitometry of 
immunoblots. All data were expressed as mean values 
± SE. Student’s t-test or one-way or two-way ANOVA 
with Bonferroni post hoc test was performed to determine 
statistically significant differences among groups (p < 
0.05). 
In vivo evaluation of JMS-053
Pharmacokinetic studies were conducted by Sai Life 
Sciences Ltd (Hinjewadi, India) using 20% 1-methyl-2-
pyrrolididone, 25% Kolliphor HS 15, and 55% 1X 
phosphate buffered saline as the vehicle and a single IP 
dose of 10 mg/kg JMS-053. Blood samples were collected 
under light isoflurane anesthesia from retro orbital plexus 
pre-dose and at eight time points, the last being at 24 h. 
Three mice were used for each time point. Sample were 
processed for analysis by protein precipitation using 
acetonitrile and analyzed by liquid chromatography/mass 
spectroscopy/mass spectroscopy. 
For in vivo antitumor experiments, HeyA8-MDR 
cells in exponential growth phase were detached from 
the monolayer with 0.25% trypsin and 20 µg/mL EDTA 
in PBS and resuspended in 10% FBS-containing RPMI, 
pelleted, and resuspended in serum-free RPMI at a 
concentration of 5 x 106 cells/mL. Female athymic nude 
mice (Envigo, Dublin, VA) were injected intraperitoneally 
(IP) (200 µL/injection) with cells and after one week mice 
(n = 10 per group) were randomized for treatment with 
vehicle (20% 1-methyl-2-pyrrolididone, 25% Kolliphor 
HS 15, and 55% 1X phosphate buffered saline) or with 
vehicle plus 10 mg/kg JMS-053. Mice were treated IP 
daily (100 µL/ injection) for 5 days with a 2-day holiday 
followed by 4 additional days of treatment before being 
sacrificed. All tumors were excised and weighed. All in 
vivo procedures were performed using the University of 
Virginia approved IACUC protocols. Animal care was 
administered in accordance to guidelines established by 
the American Association for Accreditation of Laboratory 
Animal Care. 
Statistical analysis
All statistical analyses were performed with 
GraphPad Prism 7.0. Data are presented as average (mean) 
± SD or SE. P values were calculated with Student’s t 
test for comparisons involving two groups or one-way 
or two-way ANOVA for comparisons involving >two 
groups. P < 0.05 was considered statistically significant. 
Each experiment is represented by at least three biological 
replicates and three technical replicates (per independent 
experiment).
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